Astrana Health Projects Q2 Revenue Between $965M and $1B
ASTH sits 83% above its 52-week low of $18.08.
Summary
Astrana Health has provided revenue guidance for the second quarter, expecting it to fall between $965 million and $1 billion. This forward-looking financial update is material for investors as it sets expectations for the company's near-term performance. While the company recently disclosed a material weakness in financial reporting and delayed its 10-K, this revenue guidance offers a fresh data point on its operational outlook. Traders will be assessing this range against analyst consensus to gauge potential stock price movements. The actual Q2 results and any further updates on the internal control issues will be key catalysts to watch.
At the time of this announcement, ASTH was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $18.08 to $36.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.